spacer
home > pmps > winter 2018 > open, inhale, close
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Open, Inhale, Close

Open, inhale, close has become the Holy Grail of inhaler designers – anything more demanding being considered likely to negatively influence a patient’s desire or ability to correctly use an inhaler device. Therefore, these three steps set in motion the processes needed to defeat the anatomical and physiological barriers in the lungs and nose for delivery of a drug to a local receptor or one in a remote organ. In short, the job of a pharmaceutical aerosol researcher is to overcome the complex chemical, physical, and biological barriers to drug efficacy using a device patients can and will use. The barriers go beyond science; regulations, cost, human nature, and personal experience all play a role in determining if a patient will indeed open, inhale, close. Not even 30-year veterans of Respiratory Drug Delivery (RDD®) meetings can single-handedly accumulate the vast range of knowledge, skills, and experience needed to develop an inhaled product. Pulmonary and nasal product development demands interdisciplinary collaboration and the active involvement of the patient.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Richard Dalby and Joanne Peart
Co-organisers of RDD 2018
spacer
Richard Dalby
spacer
spacer
spacer
Joanne Peart
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Get on Board with a Neat Idea

Teknomek has launched a new range of anti-microbial shadow boards developed to meet the specific needs of the pharma sector. The products are made from PVC infused with Biomaster anti-bacterial silver-ion technology, which inhibits the growth of bacteria by up to 99.9%.
More info >>

White Papers

Orthogonal Approaches for the Analysis of Protein Sequence

Ludger Ltd

One of the most important classes of biopharmaceuticals is monoclonal antibodies. They are expressed from living cells, and are consequently subject to complex biochemical pathways. Not all of these routes are fully understood, and many are sensitive to the subtlest of environmental changes. Changes such as these can affect the final biopharmaceutical sequence, structure and post-translational modifications, not to mention any changes that may occur during further purification. This often means that the final product from one batch may be different from the last in another batch. Each batch is a complicated mix of similar molecules, and analysis of the degree of batch-to-batch variation is therefore very important to the establishment of the drug's safety for medicinal use and patient administration.
More info >>

 
Industry Events

Synthetic Biology Congress

8-9 November 2018, London, UK

Oxford Global is proud to present its Synthetic Biology Congress taking place on 8-9 November 2018 in London. As part of our Genomics and Synthetic Biology UK series, our congress will bring together Over 600 delegates representing internationally renowned research & academic institutions, clinical research institutions and pharmaceutical companies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement